11:26 , Sep 28, 2018 |  BC Extra  |  Preclinical News

Two strategies block immune-mediated metastases in mice

Cold Spring Harbor Laboratory researchers and a team from two Italian institutions have published two different strategies to fight immune-mediated lung metastases. Dormant cancer cells can persist for years before awakening and proliferating, leading to...
16:02 , Apr 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Rheumatoid arthritis (RA) Patient sample and mouse studies suggest a hydrogel-based formulation of the GCCR agonist triamcinolone acetonide could help treat RA and other forms of inflammatory arthritis. The hydrogel contains injectable triglycerol monostearate that...
00:49 , Sep 9, 2017 |  BioCentury  |  Strategy

Some of the parts

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. could put the industry-leading CAR T pipeline in the hands of the company best-suited to expand the cell therapies into the as-yet-elusive solid tumor space....
18:03 , Sep 1, 2017 |  BC Week In Review  |  Company News

Gilead grabs Kite for nearly $12B

Gilead Sciences Inc. (NASDAQ:GILD) added a late-stage cancer asset and pivoted toward the chimeric antigen receptor (CAR) T cell therapy space after agreeing to acquire Kite Pharma Inc. (NASDAQ:KITE) at $180 per share in cash,...
00:56 , Aug 29, 2017 |  BC Extra  |  Company News

Gilead grabs Kite for nearly $12B

Gilead Sciences Inc. (NASDAQ:GILD) added a late-stage cancer asset and pivoted toward the chimeric antigen receptor (CAR) T cell therapy space after agreeing to acquire Kite Pharma Inc. (NASDAQ:KITE) at $180 per share in cash,...
18:16 , Aug 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies suggest inhibiting GM-CSF and MMP9 could help treat breast cancer in obese patients. In an obese genetic mouse model of breast cancer, white adipose tissue (WAT) levels of...
01:05 , Apr 21, 2017 |  BC Innovations  |  Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...
04:22 , Apr 7, 2017 |  BC Week In Review  |  Company News

Calypso, EA Pharma deal

Calypso granted EA Pharma exclusive, worldwide rights to develop and commercialize preclinical candidate CALY-001. The companies will collaborate to develop the human mAb targeting matrix metalloproteinase 9 (MMP9) to treat inflammatory bowel disease (IBD). Calypso...
19:14 , Mar 29, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers A five-protein signature could help predict the risk of ischemic stroke, MI and death from cardiovascular events in atherosclerosis patients. In serum samples from 282 patients and 403 healthy volunteers, a protein...
00:03 , Feb 22, 2017 |  BC Extra  |  Company News

Gilead buys Sarepta PRV, mum on plans

Gilead Sciences Inc. (NASDAQ:GILD) declined to comment on plans for the Priority Review voucher it acquired on Monday. The company paid $125 million to Sarepta Therapeutics Inc. (NASDAQ:SRPT), which gained the voucher last September when...